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Abstract
Background: Brain volume atrophy is observed in relapsing–remitting multiple sclerosis (RRMS).
Methods: Brain volume changes were evaluated in 23 patients with RRMS treated with interferon β-1a 44 μg given
subcutaneously (SC) three times a week (tiw) and 15 healthy controls. Percentages of whole brain and
tissue-specific volume change were measured from baseline (0 months) to 3 months, from 3 to 6 months, and
from baseline to 6 months using SIENAX Multi Time Point (SX-MTP) algorithms. Immunological status of patients
was also determined and correlations between subsets of T cells and changes in brain volume were assessed.
Results: Interferon β-1a 44 μg SC tiw in 23 patients with RRMS resulted in significant reductions in whole brain and
gray matter tissue volume early in the treatment course (baseline to 3 months; mean change; –0.95 %; P = 0.030, –1.52 %;
P = 0.004, respectively), suggesting a short-term treatment-induced pseudoatrophy effect. From baseline to 6 months,
there were significant correlations observed between decreased T- cell expression of IL-17 F and decreased whole
brain and brain tissue-specific volume.
Conclusions: These findings are consistent with the interpretation of the pseudoatrophy effect as resolution of
inflammation following treatment initiation with interferon β-1a 44 μg SC tiw, rather than disease-related tissue loss.
Trial registration: ClinicalTrials.gov; NCT01085318
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Background
Relapsing–remitting multiple sclerosis (RRMS) is associ-
ated with ongoing loss in brain volume (atrophy) [1],
and this loss contributes to irreversible neurologic impair-
ment and cognitive decline [1–4]. Several clinical trials of
disease-modifying drugs (DMDs) include some form of
brain atrophy measurement as an endpoint [5–10] or in
subgroup or post hoc analyses [1, 11–17]. Although treat-
ment has been shown to significantly reduce the rate of
brain volume loss compared with no treatment, this rate
remains substantially higher than that seen in healthy con-
trols [18]. Somewhat paradoxically, despite a long-term re-
duction in atrophy rate, initiation of anti-inflammatory
therapy itself has been associated with brief but detect-
able reductions in brain volume – an effect termed
pseudoatrophy [19]. This pseudoatrophy effect is
thought to reflect hydrodynamic changes related to
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resolution of inflammation, edema, and cellular infiltra-
tion rather than the loss of actual brain tissue [19, 20].
Because both destructive tissue atrophy and these
beneficial/benign pseudoatrophy changes may result in
similar observations of brain volume reduction and con-
found efficacy measurements [21], it is critical to disen-
tangle the two to understand the true impact of DMDs.
Some initial work was done by looking at atrophy rates
over different study time periods [9], and showed that
the effect was predominantly driven by loss in white-
matter (WM) volume; this loss was greater with higher
initial inflammatory activity as measured by gadolinium-
enhancing lesions. However, a full understanding remains
elusive owing to the relative non-specificity of in vivo
measurement methods. One important complementary
approach might be to evaluate brain volume changes in
combination with key immunological markers.
Response to DMDs and the occurrence of pseudoatro-
phy may be influenced by the underlying immunological
status of patients prior to and during treatment. A
priori, an association in patients with greater reduction
in inflammatory markers and a greater amount of pseu-
doatrophy over the same time period would be expected.
Chronic inflammation in MS is driven by production of
pro-inflammatory cytokines, such as interferon gamma
(IFN γ) and interleukin (IL)-17 by CD4+ T cells [22],
which promote the disruption of blood–brain barrier in-
tegrity, allowing egress of activated T cells into the central
nervous system (CNS), targeting of CNS-resident cells
and resulting in demyelination [23]. The presence of CD4
+ T cells and an abundance of CD8+ T cells in MS lesions
is well documented [24, 25].
The efficacy of IFN beta-1a given subcutaneously three
times a week (IFN β-1a SC tiw) for the treatment of
RRMS has been established [25–28]. However, its effect
on early changes in brain volume and its relationship to
changes in inflammatory markers have not been investi-
gated previously.
Advanced imaging techniques are able to detect whole
brain atrophy via change analysis directly between scans
rather than through the more error-prone post hoc com-
parisons of cross-sectional data of whole brain volume
measurement over time [29]. Direct measurement of whole
brain volume change is possible with approaches such as
the Structural Image Evaluation using Normalization of
Atrophy (SIENA) method [30]. This technique measures
the percent of whole brain volume change between scans
of the same subject acquired at specific time points during
the study (eg, at baseline and following treatment). How-
ever, since SIENA does not allow for discrimination of
tissue-specific atrophy, it is not possible to evaluate the
relative contributions of gray matter (GM) and WM to
whole brain atrophy in MS. As it is important to gain a
more comprehensive insight into the relative contributions
of these two compartments to MS pathophysiology, this
study used the recently described SIENAX Multi Time
Point (SX-MTP) analysis algorithm [29] to allow for the
direct and sensitive measurement of tissue-specific brain
volume changes.
Study objectives
The Rebif Advanced MRI and Immunology Pilot Trial
(NCT01085318) [31] was a two-arm, open-label, 6-
month trial conducted to evaluate remyelination/demye-
lination, brain volume, and iron deposition in the CNS,
as well as the immunological status of 23 patients with
RRMS treated with IFN β-1a 44 μg SC tiw compared
with 15 healthy controls (HCs). The objective of the
present study was to measure changes in global (whole
brain) and tissue-specific (GM and WM) percent brain
volume in patients following initiation of treatment with
IFN β-1a SC tiw. Comparisons with changes in HCs
were carried out, as were investigations of the correlations
between potential immunological biomarkers, gadolinium
(Gd)-enhancing lesions, and short-term brain volume
changes following treatment initiation.
Methods
Eligible patients were 18–65 years of age, with a diagno-
sis of RRMS according to the 2010 revised McDonald
criteria [32]. Patients received IFN β-1a SC tiw titrated
to 44 μg for 6 months. For all participants, conventional
magnetic resonance imaging (MRI) exams of the brain
were performed on a 3 T GE Signa Excite 12.0 scanner
at baseline and at 3- and 6-month follow-up visits.
Ethics, consent, and permissions
The trial was conducted in accordance with the Inter-
national Conference on Harmonisation guidelines for
Good Clinical Practice and applicable local regulations,
as well as the Declaration of Helsinki. Written informed
consent was given by patients before participation and
the protocol was approved by the Institutional Review
Board at the University at Buffalo Health Sciences.
Brain volume analysis
Percent of whole brain volume change was measured
from baseline (0 months) to 3 months, from 3 to
6 months, and from baseline to 6 months using SIENA
analysis algorithms [30]. Serial scans were co-registered
and relative edge motions (measuring expansion or con-
traction of the brain) were detected between scans and
used to extrapolate the percent change in brain volume.
SIENA measurements were improved by application of
an in-house developed inpainting technique, nonunifor-
mity correction [33], and intensity standardization [34].
Changes in GM and WM volumes were measured dur-
ing the same study periods described above using the
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SX-MTP analysis algorithms on the inpainted, corrected,
and standardized images. For GM/WM segmentation,
4D accuracy was improved through MTP modification
via longitudinal regularization of a hidden Markov ran-
dom field model.
Immunological markers of inflammation: screening
For the immunological marker analysis, CD4+ and CD8+
T-cell expression of an array of immunological markers
with known immunomodulatory properties was quanti-
fied at baseline and at 6 months. Blood samples were
collected from patients. Peripheral blood mononuclear
cells (PBMCs) were placed in serum-free medium and
stimulated with phorbol myristate acetate (50 ng/mL)
and Ionomycin (500 ng/mL; Sigma, St. Louis, MO) for
2 h and brefeldin A (1:1000 dilution; eBioscience, San
Diego, CA) for an additional 3 h for the intracellular
cytokine staining. PBMCs were fixed, permeabilized, and
stained with fluorescein-conjugated antibodies against
IFN γ, IL-4, IL-17A, IL-21, IL-22 (eBioscience, San
Diego, CA), IL-17 F, brain-derived neurotrophic factor
(BDNF; R&D Systems, Minneapolis, MN), IL-10, CD4,
and CD8 (BD Biosciences, San Jose, CA). For nerve
growth factor (NGF) staining, the cells were stained with
primary antibody against NGF (Epitomics, Cambridge,
MA), followed by staining with fluorescein isothiocyanate-
conjugated secondary antibody (BD Bioscience). The per-
cent of CD4+ and CD8+ T cells expressing each marker of
interest was determined using a BD FACSCalibur™ flow
cytometer and CellQuest software (BD Biosciences) and
gated by size and granularity.
Statistics
All statistical comparisons were planned in advance of
data collection. The Wilcoxon signed-rank test was used
to test for within-group differences in percent of brain
volume change (whole brain, GM, and WM) at each of
the study periods (from baseline to 3 months, from
3 months to 6 months, and from baseline to 6 months).
The Wilcoxon rank-sum test was used to test for differ-
ences in percent of whole brain volume change, GM,
and WM between patients and HCs during each study
period. Correction for multiple comparisons by the
Holm-Bonferroni method was applied. Spearman’s rank
correlation was used to test the correlations between im-
munological parameters, Gd-enhancing lesions at base-
line, and percent change in brain volume and GM and
WM over 3 and 6 months of treatment. No corrections
for multiple comparisons were made to the correlation
results.
Results
All 15 HCs and 21/23 patients completed the study; one
patient was lost to follow-up and one patient
discontinued owing to the investigator’s decision. The
mean age (standard deviation [SD]) of the enrolled pa-
tients was 39.9 (10.17) years and 61 % (14/23) of the pa-
tients were female. Baseline characteristics were similar
between patients and HCs; patient baseline characteris-
tics were described previously in the primary study [31].
Whole brain volume analysis
Whole brain volume analysis is shown in Table 1 and
Fig. 1. In patients, the mean (SD) change from baseline
to 3 months in brain volume was –0.95 % (1.71; P =
0.030 for difference from baseline; P = 0.090 after adjust-
ing for multiple comparisons), –0.08 % (1.36; P = 0.960)
from 3 to 6 months, and –0.91 % (1.88; P = 0.051) from
baseline to 6 months. For comparison, in HCs the mean
change from baseline to 3 months in brain volume was
0.24 % (1.07; P = 0.359), –0.32 % (1.50; P = 0.626) from 3
to 6 months, and 0.01 % (1.89; P = 0.952) from baseline
to 6 months.
GM volume analysis
GM volume analysis is shown in Table 1 and Fig. 2. The
pattern for GM was similar to that of whole brain. In pa-
tients, the mean (SD) change from baseline to 3 months
in GM volume was –1.52 % (2.41; P = 0.004 and after
adjusting for multiple comparisons, P = 0.029), –0.46 %
(3.11; P = 0.176) from 3 to 6 months, and –1.66 % (1.84;
P < 0.001 and after adjusting for multiple comparisons,
P = 0.002) from baseline to 6 months. There were no sig-
nificant differences observed for the HCs: mean change
from baseline to 3 months was 0.01 % (SD 2.42; P =
0.934), –0.60 % (2.19; P = 0.426) from 3 to 6 months,
and –0.51 % (2.47; P = 0.268) from baseline to 6 months.
WM volume analysis
WM volume analysis is shown in Table 1 and Fig. 3.
Changes in WM tissue volume of patients were not sig-
nificant at any timepoint. In patients, the mean (SD)
change from baseline to 3 months in WM volume was –
0.41 % (2.16; P = 0.390), 0.30 % (2.99; P = 0.626) from 3
to 6 months, and –0.21 % (3.20; P = 0.933) from baseline
to 6 months. In HCs, the mean (SD) change from base-
line to 3 months in WM volume was 0.51 % (1.94; P =
0.107), –0.03 % (1.96; P = 0.952) from 3 to 6 months,
and 0.58 % (2.46; P = 0.463) from baseline to 6 months.
Correlations between changes in whole brain, GM, and
WM, baseline Gd-enhancing lesions, and immunological
markers following treatment
Only 8 of the patients with RRMS had any Gd-
enhancing lesions at baseline, and there were no sig-
nificant correlations between the number or volume
of Gd-enhancing lesions at baseline and the changes
in whole brain, GM, or WM volumes.
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There were a number of significant correlations be-
tween whole brain and brain tissue-specific volumes and
immunological markers following 6 months of treatment
with IFN β-1a SC. Decreased percentage of IL-17 F-ex-
pressing CD4+ T cells from baseline to 6 months corre-
lated significantly with decreasing whole brain volume
over the same period (r = 0.51; P = 0.022; Fig. 4).
Decreased percentage of IL-17 F-expressing CD8+ T
cells from baseline to 6 months correlated with decreasing
GM volume over the same period (r = 0.47; P = 0.037;
Fig. 5). In addition, decreased percentage of IL-17 F-
expressing CD4+ T cells from baseline to 6 months
correlated with a decreasing WM volume (r = 0.46; P =
0.043; Fig. 6), suggestive of pseudoatrophy.
A higher percentage of IL-22–expressing CD4+ T cells
at baseline correlated with smaller decreases in GM
volume from baseline to 6 months (r = 0.59; P = 0.005;
Fig. 7).
Discussion
Brain volume analysis
The aim of this study was to use advanced imaging tech-
niques to measure the extent of global and tissue-
specific brain volume changes, and to examine the
Table 1 Brain volume changes in RRMS patients treated with IFN β-1a SC tiw and HCs over time
Baseline to 12 weeks 12 to 24 weeks Baseline to 24 weeks
Patients HCs Patients HCs Patients HCs
n (missinga) 23 (0) 15 (0) 21 (2) 14 (1) 21 (2) 14 (1)
Percent change in whole brain (%)
Mean (SD) –0.95 (1.712) 0.24 (1.068) –0.08 (1.358) –0.32 (1.500) –0.91 (1.880) 0.01 (0.885)
Median –0.90 0.33 0.07 –0.02 –0.63 0.05
Min, max –4.7, 2.8 –2.0, 1.7 –2.8, 2.6 –3.6, 2.2 –5.1, 2.4 –1.2, 1.8
P valueb 0.030 0.359 0.960 0.626 0.051 0.952
Adjusted P-valueb,c NS NS NS NS NS NS
P-valued 0.015 0.702 0.071
Adjusted P-valuec,d NS NS NS
Adjusted P-valuec,e NS/NS
Percent change in gray matter (%)
Mean (SD) –1.52 (2.406) 0.01 (2.415) –0.46 (3.109) –0.60 (2.189) –1.66 (1.836) –0.51 (2.472)
Median –1.89 0.80 –1.20 –0.72 –1.24 –1.31
Min, max –6.3, 2.3 –3.7, 3.7 –6.3, 9.4 –4.4, 2.5 –5.9, 1.7 –4.5, 5.1
P-valueb 0.004 0.934 0.176 0.426 <0.001 0.268
Adjusted P-valueb,c 0.0286 NS NS NS 0.0016 NS
P-valued 0.093 0.778 0.342
Adjusted P-valuec,d NS NS NS
Adjusted P-valuec,e NS/NS
Percent change in white matter (%)
Mean (SD) –0.41 (2.159) 0.51 (1.940) 0.30 (2.991) –0.03 (1.985) –0.21 (3.202) 0.58 (2.461)
Median –0.63 0.69 0.93 0.50 0.08 0.95
Min, max –5.4, 3.5 –5.1, 3.0 –6.5, 7.4 –3.4, 2.7 –5.9, 8.4 –4.5, 3.6
P-valueb 0.390 0.107 0.626 0.952 0.933 0.463
Adjusted P-valueb,c NS NS NS NS NS NS
P-valued 0.093 0.630 0.309
Adjusted P-valuec,d NS NS NS
Adjusted P-valuec,e NS/NS
aFailed analysis or missing MRI at Week 24
bFor the difference from zero within groups from the Wilcoxon signed-rank test
cAdjusted for multiple comparisons with the Holm-Bonferroni correction; NS denotes adjusted P-values ≥ 0.05
dFor the difference between IFN β-1a SC tiw and HCs from the Wilcoxon rank-sum test
eFor the difference between the first 12 weeks and the second 12 weeks within groups from the Wilcoxon signed-rank test (P-value for patients/HCs)
GM gray matter, HC healthy control; max: maximum; min: minimum, NS non-significant, SD standard deviation
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Fig. 1 Brain volume changes in RRMS patients vs HCs. Percent change in whole brain volume in RRMS patients treated with IFN β-1a SC tiw and
in HCs was measured. No P-values remained significant after adjustment for multiple comparisons. *P < 0.05, within-group difference from zero
(Wilcoxon signed-rank test). †P < 0.05, patients versus HCs (Wilcoxon rank-sum test). In the box plots, the bold line represents the median; the
boxes represent the middle 50 % of data; the top and bottom of the box represent the third and first quartiles; the open circles are outliers. The
whisker lines above and below the boxes represent the largest and smallest values that are not considered to be outliers. Means are denoted by
a ‘+’ sign. HC healthy control; IFN interferon; RRMS relapsing–remitting multiple sclerosis; SC subcutaneously; tiw three times weekly
Fig. 2 Gray matter volume changes in RRMS patients and HCs. Percent change in GM volume in RRMS patients treated with IFN β-1a SC tiw and
in HCs was assessed. P-values were for the difference from zero within groups from the Wilcoxon signed-rank test. P-values in parentheses are
those remaining significant after Holm–Bonferroni correction for multiple comparisons. *P < 0.05. **P < 0.01. ***P < 0.001. In the box plots, the bold
line represents the median; the boxes represent the middle 50 % of data; the top and bottom of the box represent the third and first quartiles;
the open circles are outliers. The whisker lines above and below the boxes represent the largest and smallest values that are not considered to be outliers.
Means are denoted by a ‘+’ sign. GM gray matter; HC healthy control; IFN interferon; RRMS relapsing–remitting multiple sclerosis; SC subcutaneously;
tiw three times weekly
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involvement of IFN β-1a 44 μg SC tiw, in the pseudoa-
trophy phenomenon in patients with RRMS. A better
understanding of the pathophysiological mechanisms in
RRMS, including a differentiation of the dynamics of
inflammation and demyelination leading to brain vol-
ume loss observed in MS, could aid in devising means
for halting disease progression and for treatment moni-
toring and optimization. In particular, the early study
period measurement from baseline to 3 months repre-
sents an opportunity to investigate acute treatment-
associated pseudoatrophy following IFN β-1a 44 μg SC
tiw therapy initiation. The investigation of brain vol-
ume loss in whole brain tissue, as well as in GM and
WM, allowed for a greater insight into the specificity of
tissue volume changes suggestive of pseudoatrophy. In
whole brain and GM, the effect of IFN β-1a SC treat-
ment was associated with a reduction in brain tissue
volume; in both cases the majority of the reduction oc-
curred shortly (within 3 months) following treatment
initiation, in comparison with the 3–6-month period, a
result that is highly consistent with an acute pseudoa-
trophy effect.
Fig. 3 White matter volume changes in RRMS and HCs. Percent change in WM volume in RRMS patients treated with IFN β-1a SC tiw and in HCs
was measured. Changes in WM volume were not significant at any timepoint. In the box plots, the bold line represents the median; the boxes
represent the middle 50 % of data; the top and bottom of the box represent the third and first quartiles; the open circles are outliers. The whisker
lines above and below the boxes represent the largest and smallest values that are not considered to be outliers. Means are denoted by a ‘+’ sign.
HC healthy control; IFN interferon; RRMS relapsing–remitting multiple sclerosis; SC subcutaneously; tiw three times weekly; WM white matter
Fig. 4 IL-17 F–expressing CD4+ T cells and brain volume changes in RRMS patients and HCs. Decreased percentage of IL-17 F–expressing CD4+ T
cells from baseline to 6 months correlated with decreased whole brain volume from baseline to 6 months in RRMS patients treated with IFN β-1a
SC tiw. HC healthy control; IFN interferon; IL interleukin; RRMS relapsing–remitting multiple sclerosis; SC subcutaneously; tiw three times weekly
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Treatment-associated pseudoatrophy has been thought
previously to be more evident in WM than in GM [9, 35].
This was not observed in the present study, where decline
in whole brain tissue volume loss appeared to be driven
by GM tissue volume loss. GM loss was more pronounced
in the first 3 months than the second 3 months, and only
loss in the first 3 months was statistically significant.
While pseudoatrophy owing to WM volume has been
noted during treatment with natalizumab [9], the longer
term brain tissue changes in RRMS and clinical measures
(such as physical and cognitive disability) have been asso-
ciated more with GM volume changes rather than loss of
WM volume [36, 37].
This conflicting finding of a GM rather than a WM
effect may be due to a number of factors. Given the
small sample size, issues of statistical power cannot be
ruled out – in fact, the observed but not statistically
significant WM volume changes were in the expected
direction and were lower from 0–3 months than from
3–6 months. Methodological effects should also be
carefully considered. Although the SIENAX-MTP
method employed has been shown to more accurately
measure GM volume change than was previously pos-
sible, it was not compared head-to-head with SIENAX
or SPM for this study. It is noteworthy, though, that
cortical GM measurement is much more susceptible to
partial volume errors owing to its thin and convoluted
nature, and that previous studies using less sensitive
analysis techniques failed to detect significant brain at-
rophy progression over a 3-month period in RRMS [38]
Fig. 5 IL-17 F–expressing CD8+ T cells and GM volume changes in RRMS. Higher percentage of IL-17 F–expressing CD8+ T cells from baseline to
6 months correlated with smaller decreases in GM volume from baseline to 6 months in treated patients with RRMS. GM gray matter; IL interleukin;
RRMS relapsing–remitting multiple sclerosis
Fig. 6 IL-17 F-expressing CD4+ T cells and WM volume changes in RRMS. Decreased percentage of IL-17 F-expressing CD4+ T cells from baseline
to 6 months correlated with decreased WM volume from baseline to 6 months in treated patients with RRMS. IL interleukin; RRMS relapsing–remitting
multiple sclerosis; WM white matter
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or in an open-label study of 30 patients with RRMS
treated with IFN β-1b [5].
If correct, though, these exploratory results merit
speculation about the potential pathophysiological basis
for the observed GM changes. Over the past decade, it
has become clear that GM plays an enormous role in
both the pathology and the clinical picture of multiple
sclerosis [39]. What remains unclear is whether the in-
volvement of GM is secondary to WM damage or a
semi-independent process [40]. Of particular relevance
to the current work is the inflammatory nature of GM
pathology. Histopathological studies have found much
lower inflammation in the GM than in the WM [41, 42].
However, biopsies have shown substantial inflammation
[43, 44]. Notably, cortical inflammation appeared in pa-
tients with early RRMS, much like the cohort studies de-
scribed here. It is also possible that different therapeutic
mechanisms of DMDs may affect any pseudoatrophy of
specific tissue compartments differently.
Correlations between brain tissue volume, Gd-enhancing
lesions, and immunological markers of inflammation
Investigating correlations between brain volume and
pro- and anti-inflammatory markers has provided some
new insight into the proposed mechanisms of action of
IFN β-1a SC tiw. The significant correlations between
the decreased percentage of pro-inflammatory IL-17 F–
expressing CD4+ or CD8+ T cells and reductions in
whole brain, GM, and WM tissue volumes are support-
ive of an early anti-inflammatory therapeutic effect for
IFN β-1a SC tiw.
The correlation between higher baseline percentage of
IL-22–expressing CD4+ T cells and less GM tissue at-
rophy from baseline to 6 months in patients is also of
potential interest. Although interpretation of cross-
sectional markers should be undertaken with care, it is
possible that higher baseline IL-22 levels may be indi-
cative of a different pseudoatrophy response – either
via less resolvable baseline inflammatory-related volu-
metric changes or via differences in treatment
response.
The comprehensive battery of immunological markers,
including BDNF, was used to screen for correlations with
brain tissue volume changes. Beyond IL-17 F and IL-22,
no further significant correlations were observed, despite
previous reports that BDNF secretion was associated
with inflammatory activity in MS lesions in the brain
and with higher WM tissue volume [45].
We did not detect a relationship between brain volume
and the resolution of Gd-enhancing lesions, likely due to
the high proportion of patients with no Gd-enhancing le-
sions at baseline.
Implications for future investigations of brain volume
changes
Our findings imply the need for caution when planning
the timing of using MRI techniques to measure disease
progression in terms of brain volume. They suggest that
the baseline for MRI measures of brain volume in pa-
tients with RRMS with active disease embarking on
DMD therapy should start only after several months of
therapy, once the pseudoatrophy effect has run its
course, rather than at the beginning of therapy, indicat-
ing a need for additional MRI measurements. Based on
these results, the pseudoatrophy effect may account for
a 1 % or more change in volume. Although seemingly
small in an absolute sense, the yearly percent brain vol-
ume change in MS may be as low as 0.5 % (and 0.1 % in
HCs). Thus, early pseudoatrophy over 3 months may
produce volume changes commensurate with 2 years of
Fig. 7 IL-22–expressing CD4+ T cells and GM volume changes in RRMS. Higher percentage of IL-22–expressing CD4+ T cells at baseline correlated
with smaller decreases in GM volume from baseline to 6 months in treated patients with RRMS. GM gray matter; IL interleukin; RRMS relapsing–remitting
multiple sclerosis
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MS disease effect, and completely mask treatment ef-
fects in clinical trials of that length. This is highly rele-
vant, as such trials are becoming more common.
It is even conceivable that in the future more accurate
MRI and analysis techniques might lead to individual pa-
tient care decisions based on rates of brain atrophy in
addition to the conventionally used lesion burden. Any
such initiatives will need to carefully account for the
pseudoatrophy effect in order to be useful.
Limitations
With the exception of GM tissue volume change from
baseline to 3 months, the statistical significance of other
associations observed was lost following adjustment for
multiple comparisons. This may be as a result of this be-
ing a pilot study with a relatively small sample size, as
well as the large number of exploratory comparisons
that underwent correction. It is also possible that the
improved SIENAX-MTP algorithm may be more power-
ful to detect real GM change than WM change [29].
Therefore, the lack of WM changes detected should be
interpreted with caution.
The additional measurement of immunology marker
changes from baseline to 3 months were also not feasible
for this study, but would have enabled the same time-
point comparison with the brain volume analysis, con-
tributing to the understanding of short-term changes in
immunology alongside pseudoatrophy.
As GM and WM atrophy occurs with aging in normal
controls [46–49], the use of the HC group in this study
as a comparison with the treated patients provided a
control for the normal aging processes but not for time
course of brain volume changes in patients with RRMS.
In future studies, an active comparator group may help
to establish the extent to which treatment-related pseu-
doatrophy is affected by treatment with IFN β-1a SC in
comparison with other DMDs. In addition, more fre-
quent measurements over the first 6 months and exten-
sion of measurement periods would allow the chance to
better delineate the time course over which pseudoatro-
phy occurs in order to be able to differentiate it from
true atrophy.
Conclusions
The results of this pilot study demonstrated a significant
reduction in whole brain volume within 3 months fol-
lowing IFN β-1a 44 μg SC tiw treatment initiation, but
not between 3 and 6 months, which is suggestive of
treatment-induced pseudoatrophy. The observed reduc-
tion in pro-inflammatory cytokine IL-17 F expression by
T cells correlating with whole brain and GM volume
decreases is consistent with an anti-inflammatory ef-
fect of IFN β-1a SC normalizing brain volume to a pre-
inflammatory level, and is consistent with the interpretation
of the pseudoatrophy effect as resolution of inflammation
rather than tissue destruction. Given these findings, at-
tempts to measure treatment effects on atrophy should
consider the use of an MRI baseline at least 3 months
after treatment initiation.
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